Skip to content

Study · Not a test of the peptide alone · 2018

4 results

Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.

Pantalone KM, Patel H, Yu M, Fernández Landó L

Diabetes, obesity & metabolism23 Mar 2018Cited by 16 (Europe PMC)

PMID29430801 (opens in a new tab)PMCIDPMC5969314 (opens in a new tab)DOI10.1111/dom.13252 (opens in a new tab)PepBankPUB-29430801
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In pooled dulaglutide-plus-insulin arms, HbA1c decreased across baseline subgroups, with the greatest reduction at higher baseline HbA1c.

    In plain wordsIn patients with T2D receiving dulaglutide plus insulin, HbA1c decreased across subgroups, most at higher baseline HbA1c.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c reduction across subgroups
    Study

    n = 445

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change
    −1.3 to −2.5%
    baseline HbA1c >9% subgroup, reported range

    Source sentences

    Summary
    At 6 months, dulaglutide 1.5 mg significantly reduced HbA1c in all subgroups (P < .001), with the highest reduction observed in patients with baseline HbA1c >9% (>74.9 mmol/mol) (range - 1.3% to -2.5% [-14.2 to -27.3 mmol/mol]).
    1 context sentence
    Summary · context
    In AWARD-4, dulaglutide plus lispro three times daily was assessed against glargine plus lispro three times daily. In AWARD-9, dulaglutide added to glargine was assessed against placebo added to glargine. Insulins were titrated to target in both trials.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    In patients with T2D receiving dulaglutide plus insulin, documented symptomatic hypoglycaemia rates were similar across baseline subgroups in both trials.

    In plain wordsIn patients with T2D receiving dulaglutide plus insulin, symptomatic hypoglycaemia rates were similar across baseline subgroups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeDocumented symptomatic hypoglycaemia across subgroups
    Study

    n: not reported in source

    Comparator
    Other baseline subgroups
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    The incidence rates of documented symptomatic and severe hypoglycaemia were similar in all subgroups in both trials.
    1 context sentence
    Summary · context
    In AWARD-4, dulaglutide plus lispro three times daily was assessed against glargine plus lispro three times daily. In AWARD-9, dulaglutide added to glargine was assessed against placebo added to glargine. Insulins were titrated to target in both trials.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    In patients with T2D receiving dulaglutide plus insulin, severe hypoglycaemia rates were similar across baseline subgroups in both trials.

    In plain wordsIn patients with T2D receiving dulaglutide plus insulin, severe hypoglycaemia rates were similar across baseline subgroups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSevere hypoglycaemia across subgroups
    Study

    n: not reported in source

    Comparator
    Other baseline subgroups
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    The incidence rates of documented symptomatic and severe hypoglycaemia were similar in all subgroups in both trials.
    1 context sentence
    Summary · context
    In AWARD-4, dulaglutide plus lispro three times daily was assessed against glargine plus lispro three times daily. In AWARD-9, dulaglutide added to glargine was assessed against placebo added to glargine. Insulins were titrated to target in both trials.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    In the two T2D trials testing dulaglutide plus insulin, the most common adverse events were gastrointestinal.

    In plain wordsIn the two T2D trials testing dulaglutide plus insulin, the most common adverse events affected the digestive system.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableGastrointestinal adverse events
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    The most common adverse events observed in each trial were gastrointestinal in nature.
    1 context sentence
    Summary · context
    In AWARD-4, dulaglutide plus lispro three times daily was assessed against glargine plus lispro three times daily. In AWARD-9, dulaglutide added to glargine was assessed against placebo added to glargine. Insulins were titrated to target in both trials.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02152371

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

Eli Lilly and Companyn = 300May 2014 to Oct 2015

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 25 Sept 2019
CompletedPhase 3Results postedNCT01191268

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

Eli Lilly and Companyn = 884Nov 2010 to Sept 2012

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Oct 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.